Generic semaglutide uptake drove roughly 40% GLP-1 sales growth at Loblaw as weight-management drug plan spend climbs
Exposed girls showed 23% fewer follicles, but researchers stop short of blaming the drug
GLP-1s top drug plan spend reports, but the retrospective data to justify the investment doesn't exist yet, says iA's Frédéric Leblanc
Canada's Drug Agency reversed its do-not-reimburse draft, and pCPA negotiations decide what plans pay next
Health Canada keeps reviewing daraxonrasib as its US price hits US$39,800 monthly
Canadian plans take the opposite turn as generic Ozempic lands at 35% of list price
